Atlanta, GA – Scibility Media – 10/27/2014.
This article discusses two biotechnology companies: Conatus Pharmaceuticals Inc(NASDAQ:CNAT) and PharmAthene, Inc.(NYSEMKT:PIP)
Coverage was initiated on Conatus Pharmaceuticals Inc(NASDAQ:CNAT) by MLV & Co on Oct. 21st, 2014. The company was assigned a “Buy” rating. The California-based biotechnology announced on Oct. 8th that its late-breaking abstract had been accepted for a poster presentation at the American Association for the Study of Liver Diseases’ annual meeting on Nov. 10th, 2014. Conatus Pharmaceuticals will be discussing data related to a recent Phase 1 clinical trial.
Additionally, the novel medicine developer also recently announced that it had appointed David T. Hagerty to the position of Executive Vice President, Clinical Development. Hagerty will oversee the company’s clinical development and operations, as well as its quality assurance and drug safety.
PharmAthene, Inc.(NYSEMKT:PIP) is a Maryland-based biotechnology company that develops and commercializes medical countermeasures against chemical threats in the United States. The company’s candidates include SparVax, a recombinant protective antigen anthrax vaccine, and Valortim, a human monoclonal antibody that would be used against anthrax. PharmAthene’s clients include the United States Department of Defense, the Biomedical Advanced Research and Development Authority, and the National Institute of Health.
On Oct. 8th, the company announced that the United States Bankruptcy Court for the Southern District of New York had lifted PharmAthene’s litigation against SIGA Technologies, a company that was ordered to pay a lump sum of damages to the Maryland-based company on Aug. 10th, 2014.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.